EL7.AI
Stocks•27 May 2026•
1 min read

MediWound Reaffirms 2026 Outlook and Updates EscharEx Clinical Timeline

Key Facts

1MediWound reported revenue of $1.5 million for the first quarter of 2026.
2The company reaffirmed its full-year 2026 revenue guidance of $24-26 million.
3Enrollment completion for the EscharEx Phase III VALUE trial is expected by the end of Q1 2027.

As biotech investors prioritize clinical pipeline progress alongside fiscal discipline, MediWound Ltd. released its financial results for the first quarter of 2026. The company reported revenue of $1.5 million for the quarter and reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million. According to reports, the company now expects to complete patient enrollment for its pivotal EscharEx Phase III VALUE trial by the end of the first quarter of 2027.

These results arrive as small-cap biotech firms face pressure to demonstrate path-to-profitability; for context, peers like Vericel reported a 25% revenue increase in their most recent quarter per market data. MediWound’s decision to maintain its annual guidance suggests a stable commercial trajectory for its existing products while it funds the high costs associated with its late-stage pharmaceutical assets.

Looking ahead, market participants will focus on the clinical timeline as a primary catalyst for valuation. Investors should watch for any further updates regarding the EscharEx trial enrollment speed which remains the company's most significant long-term value driver.